BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
BRIEF: Wai Yuen Tong profit rises six-fold on non-operational gains
Drug and healthcare products maker Wai Yuen Tong Medicine Holdings Ltd. (0897.HK) announced on Wednesday its revenue fell 5.8% year-on-year to HK$347 million ($45 million) in the six months to…
NEWS WRAP: AstraZeneca China president assisting in investigation
The British drugmaker said Leon Wang is currently cooperating with an ongoing probe, as media reported the case involved the defrauding of China’s national insurance fund By A. Au…
BRIEF: BeiGene executive reportedly detained in AstraZeneca investigation
Yin Min, chief business officer for Greater China at innovative drugmaker BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH), has been detained as part of an investigation unrelated to the company’s operations, according…
PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker
China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.
Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments
The Suzhou-based drug developer said it will commercialize its hair-loss product despite disappointing clinical testing results, as it shifts away from cancer drugs Key Takeaways: Kintor announced it will commercialize…
Inaugural operating profit fails to lift 111 Inc.
The drug distributor expects to benefit from an ongoing crackdown on corruption in its industry due to the company’s focus on distribution to pharmacies rather than hospitals Key Takeaways: 111…
Recent Articles
RELATED ARTICLES
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK -
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
